• Explore /
  • Poster
  • / Health-related quality of life (HRQoL) with enasidenib versus conventional care regimens in older patients with late-stage mutant-<i>IDH2</i> relapsed or refractory acute myeloid leukemia (R/R AML).

Health-related quality of life (HRQoL) with enasidenib versus conventional care regimens in older patients with late-stage mutant-IDH2 relapsed or refractory acute myeloid leukemia (R/R AML).

Abstract Video & Slides Poster

Authors

null

Courtney Denton Dinardo

The University of Texas MD Anderson Cancer Center, Houston, TX

Courtney Denton Dinardo , Pau Montesinos , Andre C. Schuh , Cristina Papayannidis , Paresh Vyas , Andrew H. Wei , Amer Methqal Zeidan , Clara Chen , Jennifer Lord-Bessen , Peiwen Yu , Ling Shi , Shien Guo , Iryna Bluemmert , Xin Yu , Maroof Hasan , Patricia Martin Regueira , Stéphane De Botton

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Track

Hematologic Malignancies

Sub Track

Acute Leukemia

Clinical Trial Registration Number

NCT02577406

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 7032)

DOI

10.1200/JCO.2022.40.16_suppl.7032

Abstract #

7032

Poster Bd #

263

Abstract Disclosures

Similar Posters

First Author: Prajwal Boddu

Poster

2014 ASCO Annual Meeting

Lenalidomide in the treatment of relapsed primary central nervous system lymphoma (PCNSL).

Lenalidomide in the treatment of relapsed primary central nervous system lymphoma (PCNSL).

First Author: Caroline Houillier

First Author: Marouane Maaroufi

First Author: Cyrille Touzeau